Last reviewed · How we verify
High-dose
High-dose treatment involves administering a higher-than-standard dose of a medication to achieve a specific therapeutic effect.
High-dose treatment involves administering a higher-than-standard dose of a medication to achieve a specific therapeutic effect. Used for Various conditions.
At a glance
| Generic name | High-dose |
|---|---|
| Also known as | 0.9% Saline 1.0 mL vaccination, Caffeine Citrate 40mg/kg/day |
| Sponsor | Medical University of Graz |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
The exact mechanism of high-dose treatment can vary depending on the medication and the condition being treated. However, the general principle is to use a higher dose to achieve a more pronounced effect, which can be beneficial for patients who do not respond well to standard doses.
Approved indications
- Various conditions
Common side effects
- Unknown
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- Phase 2b Controlled Study of Dosing Techniques - Part B (PHASE2)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC (PHASE2)
- Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High-dose CI brief — competitive landscape report
- High-dose updates RSS · CI watch RSS
- Medical University of Graz portfolio CI